News in Brief
Pharmacology - Oct 20
TB-PRACTECAL: Clinical Trial Yields Promising Results for Drug-Resistant Tuberculosis Treatment
TB-PRACTECAL: Clinical Trial Yields Promising Results for Drug-Resistant Tuberculosis Treatment
Administration - Oct 20
Horizon Package 2021-2027: Federal Council enables direct financing and examines further measures
Horizon Package 2021-2027: Federal Council enables direct financing and examines further measures
wire - news in brief
Category
Results 1 - 50 of 424.
TB-PRACTECAL: Clinical Trial Yields Promising Results for Drug-Resistant Tuberculosis Treatment
TB-PRACTECAL, a clinical trial led by Médecins Sans Frontières with partners including Swiss TPH, has found that a new all-oral treatment regimen for rifampicin-resistant tuberculosis (RR-TB) is safer and more effective than the current accepted standard of care.
TB-PRACTECAL, a clinical trial led by Médecins Sans Frontières with partners including Swiss TPH, has found that a new all-oral treatment regimen for rifampicin-resistant tuberculosis (RR-TB) is safer and more effective than the current accepted standard of care.
The disappearance of women researchers in times of pandemic
A team from the UNIGE and the HUG has shown that during the COVID-19 pandemic, women researchers submitted significantly less research for publication than their male counterparts did.
A team from the UNIGE and the HUG has shown that during the COVID-19 pandemic, women researchers submitted significantly less research for publication than their male counterparts did.
Net zero needs a plan
It will take more than a long-term target for 2050 to achieve climate neutrality, says Reto Knutti. Policymakers must take a consistent approach towards net zero, and define a reduction path with specific measures and interim targets.
It will take more than a long-term target for 2050 to achieve climate neutrality, says Reto Knutti. Policymakers must take a consistent approach towards net zero, and define a reduction path with specific measures and interim targets.
The Artificial Swissness exhibit - a larger than life-sized "design brain" developed by EPFL's Media x Design Lab (LDM) - is currently on display at the Seoul Biennale for Architecture and Urbanism, which runs until 31 October 2021.
Encryption provides a solution to security risks, but its flipside is that it can hinder law enforcement investigations. A new technology called client-side scanning (CSS) would enable targeted information to be revealed through on-device analysis, without weakening encryption or providing decryption keys.
80 Percent of People in Switzerland Feel Fully Integrated into Society
Only very few people in Switzerland feel highly excluded - including mostly foreigners, less educated people, young people as well as older people.
Only very few people in Switzerland feel highly excluded - including mostly foreigners, less educated people, young people as well as older people.
Human cells are like tiny, multi-purpose factories. In his research, biologist Gabriele Alessandro Fontana investigates how cells repair damaged DNA.
An EPFL scientist has pinpointed the signs of brain activity that make up our brain fingerprint, which - like our regular fingerprint - is unique. "I think about it every day and dream about it at night. It's been my whole life for five years now," says Enrico Amico, a scientist and SNSF Ambizione Fellow at EPFL's Medical Image Processing Laboratory and the EPFL Center for Neuroprosthetics.
Researchers led by the Nobel Laureate Charles Rice of The Rockefeller University and Volker Thiel of the University of Bern and Institute of Virology and Immunology have developed a non-contagious model of SARS-CoV-2 that makes it easier, faster and safer to study the virus and new variants. In addition, the realistic model can be used to better test drugs.
Valerio Piazza is creating new 3D architectures built from an inventive form of nanowire. His research aims to push the boundaries of miniaturization and pave the way to more powerful electronic devices.
Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma
Short duration infusion of Gazyvaro (obinutuzumab) is administered with a target infusion time of 90 minutes, compared to the current standard infusion time of approximately three to four hours Resul
Short duration infusion of Gazyvaro (obinutuzumab) is administered with a target infusion time of 90 minutes, compared to the current standard infusion time of approximately three to four hours Resul
Heatwaves and heavy local rainfall will increase with climate change, pushing traditional urban drainage systems to their limits.
EPFL has adopted a series of prevention, support and follow-up measures that were recommended by the School's Harassment Task Force.
Trillions of benign bacteria live in the intestine. They are kept in a continuous balance by the immune system, which thereby makes them harmless to humans.
Have you ever wanted to explore outer-space? Now you can, without leaving Earth, thanks to powerful, open-source beta software VIRUP that builds - in real-time - a virtual universe based on the most detailed contemporary astrophysical and cosmological data.
Researchers have built a footbridge prototype using reinforced-concrete blocks from walls of a building being renovated.
Translational project will create the first detailed 3D maps of human glioblastomas with an integrated 'tissue time machine' to predict response to therapies Geneva, Switzerland - The Wyss Center ann
Urban brownfields represent a major challenge to sustainable transition that remains difficult to overcome.
Sometimes you have to take things apart - separate out their components, dig into the nuts and bolts and test various hypotheses - to figure out how they work.
Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis
Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta (ofatumumab) and Mayzent (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS.
Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta (ofatumumab) and Mayzent (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS.
Technologies that interfere with our brains have great potential. But their ethical implications are such that they may require an expansion of human rights frameworks, argues Marcello Ienca.
Using heat from underground parking lots to warm apartments
EPFL spin-off Enerdrape has developed technology that can recover heat from underground parking lots and use it to warm the apartments above.
EPFL spin-off Enerdrape has developed technology that can recover heat from underground parking lots and use it to warm the apartments above.
Erster Malaria-Impfstoff von der WHO für Kinder empfohlen
Yesterday, the World Health Organization (WHO) recommended the widespread use of the malaria vaccine RTS,S/AS01, debuting a tool that could save the lives of tens of thousands of children in sub-Saharan Africa each year.
Yesterday, the World Health Organization (WHO) recommended the widespread use of the malaria vaccine RTS,S/AS01, debuting a tool that could save the lives of tens of thousands of children in sub-Saharan Africa each year.
In January 2021, Empa and BASE (Basel Agency for Sustainable Energy) were among the winners of the prestigious Inclusive Growth and Recovery Challenge by data.org, a platform for partnerships committed to build the field of data science for social impact.
Sediments in the Spöl, a small river in the very south of the canton Graubünden, are contaminated with PCBs.
Novartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticaria
Results from a Phase IIb study show all remibrutinib doses provided significant improvements in UAS7 change from baseline at week 4 and week 12 compared to placebo, and a favorable safety profile acr
Results from a Phase IIb study show all remibrutinib doses provided significant improvements in UAS7 change from baseline at week 4 and week 12 compared to placebo, and a favorable safety profile acr
"Science Wire" gives access to latest science news from universities, research centers and R&D companies.Add this page to your bookmarks
News in Brief
Pharmacology - Oct 20
TB-PRACTECAL: Clinical Trial Yields Promising Results for Drug-Resistant Tuberculosis Treatment
TB-PRACTECAL: Clinical Trial Yields Promising Results for Drug-Resistant Tuberculosis Treatment
Administration - Oct 20
Horizon Package 2021-2027: Federal Council enables direct financing and examines further measures
Horizon Package 2021-2027: Federal Council enables direct financing and examines further measures